Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SYNCOM FORMULATIONS Gains 7%; BSE HEALTHCARE Index Up 0.3%
Fri, 6 Sep 9:34

SYNCOM FORMULATIONS Gains 7%; BSE HEALTHCARE Index Up 0.3%Image source: phive2015/www.istockphoto.com

SYNCOM FORMULATIONS share price has zoomed 7% and is presently trading at Rs 23.7.

Meanwhile, the BSE HEALTHCARE index is at 43,710.8 (up 0.3%).

Among the top gainers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (up 3.5%) and ERIS LIFESCIENCES (up 3.1%).

KIMS (down 1.1%) and CAPLIN POINT (down 1.1%) are among the top losers today.

Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 8.8 to Rs 23.7, registering a gain of Rs 14.9 (up 169.9%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,804.5 to 43,710.8, registering a gain of 57.2% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 132.0%), GRANULES INDIA (up 131.0%) and Glenmark Pharma (up 125.2%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,984.0 (down 0.3%).

The top losers among the BSE Sensex today are SBI (down 1.3%) and Ultratech Cement (down 0.8%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.

In the meantime, NSE Nifty is at 25,138.0 . SBI and Coal India are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,628.1 to 81,984.0, registering a gain of 16,355.8 points (up 24.9%).

SYNCOM FORMULATIONS Financial Update...

SYNCOM FORMULATIONS net profit grew 73.6% YoY to Rs 76 million for the quarter ended June 2024, compared to a profit of Rs 44 million a year ago. Net sales rose 45.8% to Rs 873 million during the period as against Rs 598 million in April-June 2023.

For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.

The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 78.0.


Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Gains 7%; BSE HEALTHCARE Index Up 0.3%". Click here!